.webp)
Key takeaways:
- Digital gut-directed hypnotherapy can significantly reduce the cost of managing IBS, by nearly 50%, while improving accessibility and patient outcomes.
- In Dr. Simone Peters' assessment of 4,200 patients, IBS-related spending fell from $1,259 USD at baseline to $644 USD after six weeks of Nerva, later stabilizing at $502 USD.
- Digital therapeutics offer an on-demand way to extend effective DGBI management beyond face-to-face therapy, supporting better symptom management and psychological outcomes.
- Clinicians can ask about compassionate access licenses and register with the Connect portal, which offers all their patients 25% off a yearly Nerva subscription.
This blog highlights how digital gut-directed hypnotherapy can significantly reduce the cost of managing IBS – by nearly 50% – while improving accessibility and patient outcomes.
Reducing costs and increasing access – What the research reveals
Nerva co-creator Dr. Simone Peters of Monash University shared an abstract at the DDW conference about her assessment of the economic outcomes of six weeks of digital gut-directed hypnotherapy for 4,200 patients.
She was able to demonstrate how a digital therapeutic like Nerva not only has the potential to slash the long-term costs linked to IBS management by around 50%, but it’s a viable way to increase accessibility to an effective on-demand DGBI management tool beyond face-to-face therapy, leading to better symptom management and psychological outcomes.
She found that money spent on managing IBS symptoms reduced from a baseline of $1,259 USD to $644 USD after six weeks of Nerva. This trend persisted, with IBS-related expenditures stabilizing at $502 USD.
